UNASSIGNED: @entity1697 ( @entity1697 ) has been considered a promising approach for @entity5419 ( @entity5419 ). However, the current @entity1697 strategy is limited in terms of the long-term efficacy and safety. We have previously demonstrated that kakkonto, a traditional Japanese herbal medicine, suppresses the occurrence of @entity56 in a @entity19 model of ovalbumin (OVA)-induced @entity6809 , which is attributed to the induction of the @entity3744 + @entity1961 + regulatory T cells. In this study, we established an @entity1697 model using the @entity6809 @entity19 with already @entity56 and determined whether kakkonto could improve the efficacy of @entity1697 . The @entity1697 method consisted of initially administrating a very small amount of OVA and slowly increasing the amount. @entity56 decreased in the @entity1697 -treated @entity6809 @entity19 . @entity1697 significantly downregulated @entity61 immune response-related gene expression in the @entity6809 @entity19 colon, and decreased the level of @entity19 @entity8929 , a marker of mast cell degranulation in the @entity6809 @entity19 plasma. Moreover, the concomitant use of kakkonto significantly enhanced the effectiveness of @entity56 , and the combination therapy further suppressed the @entity61 immune responses and the mast cell degranulation. In addition, @entity1697 significantly increased the population of @entity3744 + @entity1961 + regulatory T cells in the @entity6809 @entity19 colon, and this population was further increased by @entity1697 in combination with kakkonto. Furthermore, the combined therapy with @entity68886 reduced the expression of RA-degrading enzyme @entity25393 mRNA in the @entity6809 @entity19 colon. These findings indicated that the combination of @entity1697 with kakkonto represents a promising approach for @entity6809 treatment.

Improvement of Therapeutic Efficacy of Oral Immunotherapy in Combination with Regulatory T Cell-Inducer Kakkonto in a XXXX Food Allergy Model.

@entity68886 :: ('MESH:C090831', 'Chemical') :: ['kakkonto'] @entity25393 :: ('232174(Tax:10090)', 'Gene') :: ['CYP26B1'] @entity6809 :: ('MESH:C565561', 'Disease') :: ['FA'] @entity8929 :: ('17224(Tax:10090)', 'Gene') :: ['mast cell protease-1'] @entity1697 :: ('MESH:D009062', 'Disease') :: ['OIT', 'Oral immunotherapy'] @entity5419 :: ('MESH:D005512', 'Disease') :: ['food allergies', 'FAs'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse', 'murine'] @entity61 :: ('15111(Tax:10090)', 'Gene') :: ['Th2'] @entity1961 :: ('12504(Tax:10090)', 'Gene') :: ['CD4'] @entity56 :: ('MESH:D004342', 'Disease') :: ['Allergic symptoms', 'OIT on the allergic symptoms', 'allergic symptoms', 'established allergic symptoms'] @entity3744 :: ('20371(Tax:10090)', 'Gene') :: ['Foxp3']
@entity19 :: (10090,Species) :: ['Murine']
